Activation of neural lineage networks and arhgef2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes

HIGHLIGHTS

• who: Shu Ning from the Department of Urologic Surgery, University of California Davis, Sacramento, CA, UC Davis Comprehensive Cancer Center, University of California have published the paper: Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes, in the Journal: (JOURNAL)
• what: The authors show that one of these genes ARHGEF2 helps to maintain survival and neuroendocrine features in prostate cancer cells. The authors assessed the neural lineage pathway in enzalutamide-resistant C4-2B MDVR cell line and NEPC patients. In the study , 95 neural lineage . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.